Speaker :

Dr. Adwaita Gore, Medical Oncologist, Mumbai

Pooled analysis of patient (pt)-reported quality of life (QOL) in the MONALEESA  (ML)-2, -3, and -7 trials of ribociclib (RIB) plus endocrine therapy (ET) to treat  hormone receptor–positive, HER2-negative (HR+/HER2?) advanced breast cancer (ABC)           

Author: Peter A. Fasching

 Citation: Annals of Oncology (2020) 31 (suppl_4): S348-S395

Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth  factor receptor 2 negative (HR+/HER2?) advanced breast cancer (ABC) treated with  endocrine therapy (ET) ± ribociclib   

Author: Debu Tripathy

Citation: SABCS 202  PD2-04